ArticleCase reports in pathology2026
A Rare Finding of Pulmonary Epithelioid Hemangioendothelioma.
Article in Case reports in pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelioid hemangioendothelioma (EHE) is a rare vascular tumor with variable presentation and malignancy. These highly uncommon tumors may arise from the liver, soft tissues, bones, and, more infrequently, from the lungs. Given its rarity, treatment approach is not unanimous, with ongoing debate regarding the relative benefits of surgical resection and radiation therapy. In support of growing efforts to standardize treatment of these tumors, we present our findings of a rare pulmonary EHE, incidentally detected in the left lung of a 65-year-old, nonsmoking female patient with a history of diabetes, hypertension, and renal cell carcinoma (RCC) in remission for 8 years after surgical resection. A surgical route was recommended, and left robot-assisted thoracoscopic wedge resections were performed. Final pathological assessment confirmed two pulmonary EHE tumors, one resected from the left upper lobe (LUL) and another from the left lower lobe (LLL) of the lung. Her postoperative course was uneventful, and at 13 months postresection, there has been no evidence of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.